Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rifamycin - Cosmo/Dr Falk Pharma/Salix

Next Previous
X
Search
Drug Profile

Rifamycin - Cosmo/Dr Falk Pharma/Salix

Alternative Names: AEMCOLO; CB-01-11; CB-01-25; M-14; Relafalk; Rifamycin controlled-release; Rifamycin CR; Rifamycin SV; Rifamycin SV MMX; Rifamycin-sodium; Rifamycin-SV-sodium; Stadmycin

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cosmo Pharmaceuticals
  • Developer Cosmo Pharmaceuticals; Dr Falk Pharma; Hunter Holmes Mcguire Veteran Affairs Medical Center; RedHill Biopharma; Salix Pharmaceuticals
  • Class Antibacterials; Antirheumatics; Antituberculars; Rifamycins; Small molecules
  • Mechanism of Action DNA-directed RNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pouchitis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Traveller's diarrhoea
  • Phase II Diverticulitis; Hepatic encephalopathy; Intestinal infections; Irritable bowel syndrome
  • Preclinical Pouchitis
  • Discontinued Clostridium difficile infections

Most Recent Events

  • 04 Sep 2023 Rifamycin SV MMX® 200mg licensed to Adalvo for the treatment of Travellers’ Diarrhea (PO) in Asia-Pacific, Europe, Latin-America, Middle-East, North-Africa
  • 06 May 2023 Preclinical trials in Pouchitis in Ireland (Rectal)
  • 06 May 2023 Interim pharmacodynamics data from a preclinical studies in pouchitis presented at the Digestive Disease Week 2023 (DDW-2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top